TIDMSCLP
RNS Number : 6889N
Scancell Holdings Plc
26 September 2019
26 September 2019
Scancell Holdings plc
("Scancell" or the "Company")
Scancell to present six posters at the CRI-CIMT-EATI-AACR
International Cancer Immunotherapy Conference
Scancell, the developer of novel immunotherapies for the
treatment of cancer, will be presenting at the 5(th)
CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference,
being held at the Espace Grande Arche de la Defense in Paris,
France, from 25-28 September 2019.
The 2019 meeting hosted by the Cancer Research Institute (CRI),
the Association for Cancer lmmunotherapy (CIMT), the European
Academy of Tumor Immunology (EATI), and the American Association
for Cancer Research (AACR) will focus on "Translating Science into
Survival," and feature talks from more than 50 leaders in the field
covering all areas of inquiry in cancer immunology and
immunotherapy.
Starting today, Professor Lindy Durrant, Ph.D., Chief Scientific
Officer of Scancell and Professor of Cancer Immunotherapy at the
University of Nottingham, and members of her research team will be
presenting six posters, including one on FG2811 a new
ultra-specific antibody with the ability to induce human stem
memory T cell (TSCM) proliferation and differentiation. TSCM cells
are a rare subset of white blood cells with the stem cell-like
ability to self-renew and have capacity to differentiate into other
T cell subsets that proliferate and accelerate anti-tumour
immunity. Therefore, FG2811 has the potential to be utilised in
vivo for cancer immunotherapy or to provide cells for CAR-T or TCR
adoptive cell therapies.
The additional poster presentations contribute to the continued
scientific understanding of Scancell's cancer immunotherapy
platform, Moditope(R), targeting stress induced post translational
modifications (siPTMs). These data are important validators as
Scancell advances the lead Moditope programme, Modi-1, towards the
clinic and also to the continued preclinical advancement of
Modi-2.
The poster presentations are as follows:
-- "An ultraspecific monoclonal antibody (FG2811) recognises a
novel marker on stem memory T cells and induces cell proliferation
and differentiation in vitro and in vivo" by Scancell, Nottingham
University and Josep Carreras Leukaemia Research Institute
-- "Post-translationally modified antigens are good targets for
cancer immunotherapy but some patients have antigen specific T-regs
that may need to be neutralized" by Nottingham University and
Scancell
-- "Improving selection criteria for post translationally
modified CD4 epitopes using computer algorithms" by Scancell and
Nottingham University
-- "Carbamylation of lysine residues mediated by MDSCs in the
tumour environment make excellent targets for CD4 T cell mediated
cancer immunotherapy" by Scancell, Nottingham University and
Nottingham Trent University
-- "Targeting citrullinated vimentin and enolase with cytotoxic
CD4 T cells relies upon MHC-II expression by tumors, reduces
myeloid suppressor cells and directly kills tumor cells" by
Scancell, ISA Pharmaceuticals and Nottingham University
-- "Citrullinated glucose-regulated protein 78 is a candidate
target for cancer immunotherapy" by Scancell and Nottingham
University
All posters will be made available on the Company's website, at
https://www.scancell.co.uk/scientific-papers-posters
For Further Information:
Scancell Holdings plc
Dr John Chiplin, Chairman +44 (0) 20 3727 1000
Dr Cliff Holloway, CEO
Panmure Gordon (UK) Limited
(Nominated Adviser and Corporate
broker)
Freddy Crossley/Emma Earl +44 (0) 20 7886 2500
FTI Consulting
Simon Conway/Natalie Garland-Collins +44 (0) 20 3727 1000
About Scancell
Scancell is developing novel immunotherapies for the treatment
of cancer based on its ImmunoBody(R), Moditope(R) and AvidiMab(TM)
technology platforms.
ImmunoBody(R) vaccines target dendritic cells and stimulate both
parts of the cellular immune system. They have the potential to be
used as monotherapy or in combination with checkpoint inhibitors
and other agents. This platform has the potential to enhance tumour
destruction, prevent disease recurrence and extend survival.
-- SCIB1, the lead programme, is being developed for the
treatment of melanoma. A phase 1/2 clinical trial has so far
successfully demonstrated survival data of more than five
years.
-- SCIB2 is being developed for the treatment of non-small cell
lung cancer and other solid tumours. Scancell has entered into a
clinical development partnership with Cancer Research UK (CRUK) for
SCIB2.
Moditope(R) represents a completely new class of potent and
selective immunotherapy agents based on stress-induced
post-translational modifications (siPTM). It stimulates the
production of killer CD4 T cells which overcome the immune
suppression induced by tumours, allowing activated T cells to seek
out and kill tumour cells that would otherwise be hidden from the
immune system. Moditope(R) alone, or in combination with other
agents, has the potential to treat a wide variety of cancers.
-- Modi-1 is being developed for the treatment of solid tumours
including triple negative breast cancer, ovarian cancer and head
and neck cancer.
AvidiMab(TM) is a patent protected technology platform which
increases the avidity of human antibodies by promoting non-covalent
Fc-Fc interactions. This modification induces the direct tumour
cell killing properties of Scancell's anti-glycan monoclonal
antibodies (mAbs) but has broad potential to increase the avidity
or potency of any therapeutic monoclonal antibody including those
being developed for autoimmune diseases, as well as cancer.
For further details, please see our website:
www.scancell.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCEELFLKKFEBBZ
(END) Dow Jones Newswires
September 26, 2019 02:00 ET (06:00 GMT)
Grafico Azioni Scancell (LSE:SCLP)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Scancell (LSE:SCLP)
Storico
Da Mar 2023 a Mar 2024